Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for ARDX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -17.32M
March 31, 2026 -36.26M
December 31, 2025 -42.48M
September 30, 2025 -53.62M
June 30, 2025 -53.49M
March 31, 2025 -47.54M
December 31, 2024 -44.81M
September 30, 2024 -63.34M
June 30, 2024 -85.30M
March 31, 2024 -80.64M
December 31, 2023 -89.72M
September 30, 2023 -66.72M
June 30, 2023 -70.68M
March 31, 2023 -87.22M
December 31, 2022 -70.04M
September 30, 2022 -123.80M
June 30, 2022 -132.96M
March 31, 2022 -135.95M
December 31, 2021 -152.55M
September 30, 2021 -130.67M
June 30, 2021 -115.96M
March 31, 2021 -100.71M
December 31, 2020 -81.44M
Date Value
September 30, 2020 -74.98M
June 30, 2020 -75.72M
March 31, 2020 -84.52M
December 31, 2019 -76.48M
September 30, 2019 -83.78M
June 30, 2019 -90.19M
March 31, 2019 -80.38M
December 31, 2018 -70.27M
September 30, 2018 -47.14M
June 30, 2018 -39.16M
March 31, 2018 -45.23M
December 31, 2017 -65.19M
September 30, 2017 -96.45M
June 30, 2017 -102.23M
March 31, 2017 -103.05M
December 31, 2016 -92.53M
September 30, 2016 -87.58M
June 30, 2016 -74.56M
March 31, 2016 -79.88M
December 31, 2015 -71.84M
September 30, 2015 -54.03M
June 30, 2015 -47.91M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
REGENXBIO, Inc. -246.67M
ACADIA Pharmaceuticals, Inc. 160.32M
Alnylam Pharmaceuticals, Inc. 885.89M
Anika Therapeutics, Inc. 5.977M
Savara, Inc. -110.38M